Bioject third one fourth revenues increase to $3.

, a respected developer of needle-free medication delivery systems, reported monetary results for the 3rd quarter ended September 30 today, 2011. Bioject reported revenues of $3.september 30 1 million for the quarter ended, 2011, in comparison to revenues of $1.5 million in the comparable 2010 period. Revenue had been $2.9 million in the 2011 period in comparison to $1.4 million in the comparable 2010 period. Permit and technology costs were $245,september 30 000 for the one fourth ended, 2011, in comparison to $91,000 in the similar 2010 period. Net gain allocable to common shareholders for the 3rd one fourth of 2011 was $372,000 in comparison to a net reduction allocable to common shareholders of $357,000 in the similar 2010 period.And actually, after seven days, mice injected with pre-treated cells not only had three times more cardiomyocytes than control pets, but their heart function was also far better supporting the theory that heart regeneration had, in fact, occur. These results suggest that cardiac stem cells, if induced to increase their internal calcium oscillations, could be activated to regenerate dead heart tissue after a heart attack stopping function loss and, as result, the threat of future heart failure also. If Martins, Clavo and co-workers’ results can be transferred to individuals they may pave the way to a totally different, and far better, approach to the treatment of cardiovascular diseases, something particularly important in the times we live in.